This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PRTO Proteon Therapeutics (PRTO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrendsBuy This Stock About Proteon Therapeutics Stock (NASDAQ:PRTO) 30 days 90 days 365 days Advanced Chart Get Proteon Therapeutics alerts:Sign Up Key Stats Today's Range$2.80▼$2.9250-Day Range$0.84▼$25.1352-Week Range$0.22▼$3.94Volume133,655 shsAverage Volume1.11 million shsMarket Capitalization$64.10 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts. Read More Receive PRTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Proteon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PRTO Stock News HeadlinesProQR Therapeutics price target raised to $4 from $2.50 at ChardanNovember 9, 2024 | markets.businessinsider.comProtara Therapeutics (TARA) Earnings Dates & ReportsNovember 1, 2024 | investing.comWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington. July 5 at 2:00 AM | Altimetry (Ad)ProQR Therapeutics upgraded to Strong Buy from Outperform at Raymond JamesOctober 29, 2024 | markets.businessinsider.comPROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On MondayOctober 28, 2024 | msn.comProQR Announces Major Share Offering AgreementOctober 25, 2024 | markets.businessinsider.comSeaport raises $225m to advance portfolio of neuropsychiatric prodrugsOctober 22, 2024 | msn.comProdrugs and patents: Enhancing therapy adherence and reducing side effectsSeptember 11, 2024 | msn.comSee More Headlines PRTO Stock Analysis - Frequently Asked Questions How were Proteon Therapeutics' earnings last quarter? Proteon Therapeutics Inc (NASDAQ:PRTO) posted its earnings results on Thursday, October, 31st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01. What other stocks do shareholders of Proteon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Proteon Therapeutics investors own include Bristol Myers Squibb (BMY), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), ImmunoGen (IMGN), Onconova Therapeutics (ONTX), Sierra Oncology (SRRA) and Tonix Pharmaceuticals (TNXP). Company Calendar Last Earnings10/31/2019Today7/05/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:PRTO CIK1359931 Webwww.proteontherapeutics.com Phone781-890-0102FaxN/AEmployees17Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.73 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-118.68% Debt Debt-to-Equity RatioN/A Current Ratio5.98 Quick Ratio5.98 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.06) per share Price / Book-48.17Miscellaneous Outstanding Shares22,179,000Free FloatN/AMarket Cap$64.10 million OptionableNot Optionable Beta0.60 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:PRTO) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Proteon Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Proteon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.